T1	Participants 0 17	Metformin therapy
T2	Participants 27 150	ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome.
T3	Participants 392 442	randomized, double-blind, placebo-controlled study
T4	Participants 464 501	clinic of a tertiary referral center.
T5	Participants 513 567	Fifty-six women with clomiphene citrate-resistant PCOS
T6	Participants 585 595	Two cycles
T7	Participants 812 1005	Insulin, T, DHEAS, FSH, LH, body mass index (BMI), waist-to-hip ratio, endometrial thickness, cervical score, ovulation, and pregnancy rates in clomiphene-induced cycles after metformin therapy
T8	Participants 1378 1433	higher cumulative pregnancy rate in the metformin group
T9	Participants 1444 1524	there was no significant difference in the pregnancy rate between the two groups
T10	Participants 1540 1737	Metformin therapy not only decreases hyperandrogenism and insulin resistance but also improves ovulation rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with PCOS.
